Fei Yan

Fei Yan

Auto-generated profile, based on publicly available information

Fei Yan

Affiliated Hospital of Qingdao University Qingdao China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Arthritis & Rheumatology
Verified
Journal Article
Open access
FYFei Yan
Fei Yan
XXXiaomei Xue
Xiaomei Xue
JLJie Lu
Jie Lu
NDNicola Dalbeth
Nicola Dalbeth
HQHan Qi
Han Qi
CLChanggui Li
Changgui Li
Objective: The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion; however, the standard urate‐lowering therapy (ULT) recommendation is first‐line xanthine oxidase inhibitor (XOI), irrespective of the cause of hyperuricemia. This comparative effectiveness clinical trial was undertaken to compare first‐line nontitrated low‐dose benzbromarone (LDBen) uricosuric therapy to XOI ULT with low‐dose febuxostat (LDFeb) in gout patients with renal uric acid underexcretion.Methods: We conducted a prospective, randomized, single‐center, open‐label trial in men with gout and renal uric acid underexcretion (defined as fractional excretion of urate <5.5% and uric acid excretion ≤600 mg/day/1.73 m2). A total of 196 participants were randomly assigned to receive LDBen 25 mg daily or LDFeb 20 mg daily for 12 weeks. All participants received daily urine alkalization with oral sodium bicarbonate. The primary end point was the rate of achieving the serum urate target of <6 mg/dl.Results: More participants in the LDBen group achieved the serum urate target than those in the LDFeb group (61% compared to 32%, P < 0.001). Rates of adverse events, including gout flares and urolithiasis, did not differ between groups, with the exception of greater transaminase elevation in the LDFeb group (4% for LDBen compared to 15% for LDFeb, P = 0.008).Conclusion: Compared to LDFeb, LDBen has superior urate‐lowering efficacy and similar safety in treating relatively young and healthy patients with renal uric acid underexcretion–type gout.

8 August 2023 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
FYFei Yan
Fei Yan
HZHui Zhang
Hui Zhang
XYXuan Yuan
Xuan Yuan
XWXuefeng Wang
Xuefeng Wang
MLMaichao Li
Maichao Li
ZLZhen Liu
Zhen Liu
Objectives: The deposition of monosodium urate (MSU) crystals within synovial joints and tissues is the initiating factor for gout arthritis. Thus, MSU crystals are a vital tool for studying gout’s molecular mechanism in animal and cellular models. This study mainly compared the excellence and worseness of MSU crystals prepared by different processes and the degree of inflammation induced by MSU crystals. Methods: MSU crystals were prepared using neutralization, alkali titration, and acid titration methods. The crystals’ shape, length, quality, and uniformity were observed by polarized light microscopy and calculated by the software Image J. The foot pad and air pouch models were used to assess the different degrees of inflammation induced by the MSU crystals prepared by the three different methods at different time points. Paw swelling was evaluated by caliper. In air pouch lavage fluid, inflammatory cell recruitment was measured by hemocytometer, and the level of IL-1β, TNF-α, and IL-18 by ELISA. Inflammatory cell infiltration was assayed by immunohistochemistry of air pouch synovial slices. Results: For the preparation of MSU crystals with the same uric acid, the quantity acquired by the alkalization method was highest, followed by neutralization, with the acid titration method being the lowest. The crystals prepared by neutralization were the longest. The swelling index of the foot pad induced by MSU crystals prepared by acid titration was significantly lower than that of the other methods at 24 h. The inflammatory cell recruitment and level of IL-1β, TNF-α, and IL-18 in air pouch lavage fluid were lowest in animals with crystals prepared by acid titration. IL-1β secretion induced by MSU crystals prepared by acid titration was significantly lower than that of the other two groups, but there was no significant difference in IL-18 secretion between the three groups in THP-1 macrophages and BMDMs. Conclusions: All three methods can successfully prepare MSU crystals, but the levels of inflammation induced by the crystals prepared by the three methods were not identical. The degree of inflammation induced by MSU crystals prepared by neutralization and alkalization is greater than by acid titration, but the quantity of MSU crystals obtained by the alkalization method is higher and less time-consuming. Apparently, the window of inflammation triggered by acid titration preparation is shorter compared to other forms of crystal preparation. Overall, MSU crystals prepared by the alkaline method should be recommended for studying the molecular mechanisms of gout in animal and cellular models.

24 August 2025 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
CLChanggui Li
Changgui Li
MSMingshu Sun
Mingshu Sun
ZLZhen Liu
Zhen Liu
DLDetian Li
Detian Li
CWChangqian Wang
Changqian Wang
JZJiajun Zhao
Jiajun Zhao
Objective: The aim of this updated guideline is to provide comprehensive recommendations for the management of gout in patients with common comorbidities, such as chronic kidney disease (CKD), cardiovascular disease (CVD), diabetes, osteoarthritis (OA), and gastrointestinal disorders.Methods: This guideline was developed by a multidisciplinary expert panel consisting of specialists in endocrinology, rheumatology, nephrology, cardiology, gastroenterology, and methodology. The development process adhered to standard methodologies, including PICO (population, intervention, comparator, and outcomes) question deconstruction, systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) for evidence and recommendation evaluation, Delphi voting, and expert consensus.Results: The guideline presents 26 evidence‐based recommendations addressing seven clinical questions for patients with hyperuricemia and gout in the context of comorbidities. Key recommendations include the maintenance of strict serum urate targets, particularly for patients with CKD stage ≥ 3, chronic gouty arthritis, and OA, in order to prevent disease progression. In patients with CVD or diabetes, intra‐articular triamcinolone is preferred over systemic glucocorticoids. Prioritized anti‐inflammatory treatments for patients with CKD, gastrointestinal diseases, and OA are recommended. The guideline also introduces emerging therapies, such as interleukin‐1 inhibitors and selective urate transport inhibitors, as potential treatment options for refractory cases.Conclusion: The update offers a comprehensive, patient‐centered approach to managing gout, particularly in individuals with associated comorbidities. Multidisciplinary collaboration and emerging new treatments and evidence ensure the optimization of the recommendations.

20 February 2024 in Arthritis Care & Research
Verified
Journal Article
Closed access
XXXiaomei Xue
Xiaomei Xue
MSMingshu Sun
Mingshu Sun
FYFei Yan
Fei Yan
NDNicola Dalbeth
Nicola Dalbeth
YHYuwei He
Yuwei He
CLChanggui Li
Changgui Li

28 August 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
AJAichang Ji
Aichang Ji
YSYang Sui
Yang Sui
XXXiaomei Xue
Xiaomei Xue
XJXiapeng Ji
Xiapeng Ji
WSWenrui Shi
Wenrui Shi
CLChanggui Li
Changgui Li
Objective: Mechanisms underlying the adolescent‐onset and early‐onset gout are unclear. This study aimed to discover variants associated with early‐onset gout.Methods: We conducted whole‐genome sequencing in a discovery adolescent‐onset gout cohort of 905 individuals (gout onset 12 to 19 years) to discover common and low‐frequency single‐nucleotide variants (SNVs) associated with gout. Candidate common SNVs were genotyped in an early‐onset gout cohort of 2,834 individuals (gout onset ≤30 years old), and meta‐analysis was performed with the discovery and replication cohorts to identify loci associated with early‐onset gout. Transcriptome and epigenomic analyses, quantitative real‐time polymerase chain reaction and RNA sequencing in human peripheral blood leukocytes, and knock‐down experiments in human THP‐1 macrophage cells investigated the regulation and function of candidate gene RCOR1.Results: In addition to ABCG2, a urate transporter previously linked to pediatric‐onset and early‐onset gout, we identified two novel loci (Pmeta < 5.0 × 10−8): rs12887440 (RCOR1) and rs35213808 (FSTL5‐MIR4454). Additionally, we found associations at ABCG2 and SLC22A12 that were driven by low‐frequency SNVs. SNVs in RCOR1 were linked to elevated blood leukocyte messenger RNA levels. THP‐1 macrophage culture studies revealed the potential of decreased RCOR1 to suppress gouty inflammation.Conclusion: This is the first comprehensive genetic characterization of adolescent‐onset gout. The identified risk loci of early‐onset gout mediate inflammatory responsiveness to crystals that could mediate gouty arthritis. This study will contribute to risk prediction and therapeutic interventions to prevent adolescent‐onset gout.

9 November 2023 in Arthritis Care & Research
Verified
Journal Article
Open access
YHYuwei He
Yuwei He
XXXiaomei Xue
Xiaomei Xue
NDNicola Dalbeth
Nicola Dalbeth
RTRobert Terkeltaub
Robert Terkeltaub
YCYing Chen
Ying Chen
MSMingshu Sun
Mingshu Sun
Objective: To assess post‐COVID‐19 vaccination gout flare risk with differing baseline flare burden.Methods: We prospectively studied gout patients with infrequent or frequent flares, defined as ≤1 flare/year or ≥2 flares/year, respectively. COVID‐19 vaccine‐naive patients managed with urate‐lowering therapy between February and June 2021 were included and voluntarily decided on vaccination. Participants were followed for 12 weeks after enrollment or first vaccine dose. Gout flares and risk factors were compared between groups.Results: Of 530 participants, 308 (58.1%) had infrequent flares and 222 (41.9%) had frequent flares at baseline, with 248 (142 infrequent and 106 frequent) receiving two‐dose COVID‐19 vaccination. Vaccination increased cumulative flare incidence at 12 weeks in the infrequent but not the frequent flare group (26.1% vs 10.8%, P = 0.001, compared with 60.4% vs 65.5%, P = 0.428). Flare incidence in the final 4 weeks of observation decreased significantly only in the vaccinated infrequent flare group (4.3% vs 12.0%, P = 0.017). Multivariable analyses showed that vaccination (odds ratio [OR] 2.82, 95% confidence interval [95% CI] 1.50–5.30, P = 0.001), flare in the preceding year (OR 1.95, 95% CI 1.03–3.71, P = 0.04), and body mass index (OR 1.09, 95% CI 1.01–1.19, P = 0.03) were independently associated with increased flare risk in the infrequent flare group. Baseline serum urate (mg/dl) was an independent risk factor in the frequent flare group (OR 1.23, 95% CI 1.05–1.45, P = 0.012).Conclusion: COVID‐19 vaccination was associated with increased early gout flares only in patients with previously infrequent flares. image